IKZF1 and plasma cell myeloma: Furthermore, CelMoDs, a class of IKZF1/3 degraders developed by Bristol-Myers Squibb (such as CC-92480, CC-220, and CC-99282), have entered clinical studies for the treatment of relapsed or refractory multiple myeloma (RRMM) (75).